Showing 4461-4470 of 5771 results for "".
- Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindnesshttps://modernod.com/news/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-for-treating-blindness/2478474/Novartis announced that it has acquired Vedere Bio, adding a new platform for AAV-based delivery of gene therapies and an optogenetics program. The acquisition will enable Novartis to advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
- Regenxbio to Receive $80 Million Milestone Payment from Novartishttps://modernod.com/news/regenxbio-to-receive-80-million-milestone-payment-from-novartis/2478475/Regenxbio announced that it will receive a milestone payment of $80 million from Novartis based upon the achievement of $1 billion in cumulative net sales of Zolgensma. Regenxbio expects to recognize this revenue in the third quarter of 2020. “Zolgensma is a transformative, one-time
- Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039https://modernod.com/news/nicox-granted-new-patent-for-ncx-470-extending-exclusivity-in-europe-to-2039/2478471/Nicox announced that the European Patent Office has granted a formulation patent for NCX 470, extending the European exclusivity to 2039. The equivalent U.S. patent has already been granted, and NCX 470 is also covered by granted composition of matter patents. “We are pleased that our form
- Lilly Reaches Deal to Supply US With COVID-19 Antibody Treatment Bamlanivimabhttps://modernod.com/news/lilly-reaches-deal-to-supply-us-with-covid-19-antibody-treatment-bamlanivimab/2478472/Eli Lilly announced that it has signed a $375-million agreement with the US government to supply 300,000 vials of bamlanivimab, an investigational neutralizing antibody treatment for COVID-19. The company recently submitted a request to the FDA seeking emergency-use authorization (EUA) for bamlan
- Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-ophthalmic-solution-for-the-treatment-of-patients-with-dry-eye-disease/2478473/Aerie Pharmaceuticals announced the commencement of COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and
- RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trialhttps://modernod.com/news/regenerx-joint-venture-enrolls-last-subject-in-phase-3-dry-eye-trial/2478468/RegeneRx Biopharmaceuticals announced that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome. Completion of treatment and follow-up for the last subject is anticipated to be by the end of Novem
- Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countrieshttps://modernod.com/news/santen-and-aerie-conclude-exclusive-license-agreement-for-rhopressa-and-rocklatan-in-japan-and-several-other-asian-countries/2478469/Santen Pharmaceutical and Aerie Pharmaceuticals announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, along with rights for several other Asian countries. Rhopressa (netarsudil ophthalmic solution) 0
- CVS Pharmacy Launches QuickRenew At-Home Contact Lens Prescription Renewal Toolhttps://modernod.com/news/cvs-pharmacy-launches-quickrenew-at-home-contact-lens-prescription-renewal-tool/2478465/CVS Pharmacy announced the launch of QuickRenew, an online contact lens prescription renewal tool currently available on the
- Blanchard Contact Lenses Adds Paragon CRT to Product Portfoliohttps://modernod.com/news/blanchard-contact-lenses-adds-paragon-crt-to-product-portfolio/2478464/Blanchard Contact Lenses announced that it has expanded its product portfolio in the United States to include Paragon CRT and Paragon CRT Dual Axis ortho-k lenses. Paragon CRT and Paragon CRT Dual Axis are reverse geometry corneal lenses manufactured in high-Dk gas permeable lens material
- Bausch + Lomb Introduces SimplifEYE IOL Delivery System for Envista Toric and Monofocal Preloaded IOLshttps://modernod.com/news/bausch-lomb-introduces-simplifeye-iol-delivery-system-for-envista-toric-and-monofocal-preloaded-iols/2478461/Bausch + Lomb announced the introduction of the SimplifEYE IOL delivery system, which is available exclusively for the enVista MX60PL and the enVista toric MX60PT, the first preloaded toric IOL available in the United States. “Surgeons recognize that using a preloaded IOL system can stream